INVEGA SUSTENNA® is approved for the treatment of schizoaffective disorder
Outpatient Sample Program
The Outpatient Sample Program is designed to help you receive samples of the product free of charge, to help initiate patients on INVEGA SUSTENNA®. Starting doses will be mailed directly to your participating facility.
By registering for the program, you recognize that this is a product sample submitted for the needs of your patients and will not be sold, traded, bartered, returned for credit, or submitted for third-party reimbursement.
If you have questions, please contact our Customer Service Center at 1-855-463-1912, Monday through Friday, between 8 am and 8 pm ET.
INVEGA SUSTENNA® Inpatient Hospital Pharmacy Free Trial Program
The INVEGA SUSTENNA® Inpatient Hospital Pharmacy Free Trial Program is available only to inpatient hospital pharmacies that are unable to accept PDMA samples. Janssen Pharmaceuticals, Inc., is offering patients determined to be appropriate for a trial of INVEGA SUSTENNA® the opportunity to receive up to 2 free trial units per calendar year per patient, subject to quantity limits. To receive free trial units for patients, annual enrollment and adherence to program rules are required.
Please see below for an overview of the program rules for the INVEGA SUSTENNA® Inpatient Hospital Pharmacy Free Trial Program. In order to receive free trial units for your patients, you must agree and adhere to all program rules, which can be found at inpatientfreetrialprogram.com
- The free trial product requested must be for an inpatient hospital licensed as a hospital under applicable state law
- The program is only available for an inpatient hospital that is unable to accept PDMA samples
- Retail pharmacies are not eligible for program participation
- There is no requirement for subsequent use of INVEGA SUSTENNA® for any patient receiving a free trial unit
- This program, as amended from time to time, will be available through December 31, 2019. Program available only in the United States and Puerto Rico*†
Annual enrollment is required with valid state license numbers from at least 1 of each of the following:
(1) Inpatient hospital pharmacist
(2) Inpatient hospital pharmacy
(3) Inpatient hospital
(4) Inpatient hospital prescriber
Patient and prescriber quantity limits
- Pharmacists may order and receive for patients determined to be appropriate up to 2 free trial units per calendar year per patient
- Inpatient hospital pharmacies and inpatient hospitals must have the ability to track utilization of this program by each patient and establish adequate controls to ensure that product received under this program is appropriately segregated and tracked as if it were a PDMA sample
- Additional quantity limits may apply
Prohibition on separate billing
- Free trial units are commercially labeled as trade product and not labeled as sample products
- Do not separately bill the patient, the patient's insurance carrier, or the government for any INVEGA SUSTENNA® dispensed as part of this program
- Free trial product received pursuant to this program may not be sold, traded, bartered, or returned for credit
- Orders requesting free trial units must be submitted within 30 days of the dispense date
Pharmacist acknowledgement of receipt (AOR)
- Failure to complete AOR(s) within a timely manner will result in suspension of the program
- Hospital, pharmacy, pharmacist, and prescriber information and the free trial disbursement(s) may be reported as required by state or federal law. Once reported, this information may be made available for public view
Patient insurance benefits investigation and other Janssen CarePath program offerings are provided by third-party service providers for Janssen CarePath, under contract with Janssen Pharmaceuticals, Inc. (Janssen). Janssen CarePath is not available to patients participating in the Patient Assistance Program offered by Johnson & Johnson Patient Assistance Foundation. The availability of information and assistance may vary based on the Janssen medication, geography and other program differences. Janssen CarePath assists healthcare providers (HCPs) in the determination of whether treatment could be covered by the applicable third-party payer based on coverage guidelines provided by the payer, and patient information provided by the HCP under appropriate authorization following the provider’s exclusive determination of medical necessity. This information and assistance are made available as a convenience to patients, and there is no requirement that patients or HCPs use any Janssen product in exchange for this information or assistance. Janssen assumes no responsibility for and does not guarantee the quality, scope, or availability of the information and assistance provided. The third-party service providers, not Janssen, are responsible for the information and assistance provided under this program. Each HCP and patient is responsible for verifying or confirming any information provided. All claims and other submissions to payers should be in compliance with all applicable requirements.